TP53 and prostate cancer: The inhibition of G1/S transition, accompanied by the decreased proliferation caused by 2, was observed in all cancer cell lines used in this experiment (LAPC-4—metastatic prostate, established from lymph nodes in SCID mice; PC3—androgen receptor null, p53-null, metastatic (bone) prostate cancer; and DU145—androgen receptor, p53-mutated, metastatic (brain) prostate cancer).